Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 22
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
PTC Therapeutics Inc
PTCT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$63.24
0.63
1%
Ult. Agg.: Oct 22, 9:54 AM
$61.91
-0.71
-1.13%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Utili:
I risultati di Q3 2026 tra 7 giorni da adesso in gio ott 29th, dopo la chiusura del mercato
Conference call:
Conference call programmata per tra 7 giorni alle 4:30 PM
Clicca per vedere il webcast
PTC Therapeutics Financials
PTC Therapeutics (PTCT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
PTC Therapeutics Raises FY2026 Sales Guidance from $1.080B-$1.180B to $1.180B-$1.280B vs $1.196B Est
PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $1.080 billion-$1.180 billion to $1.180 billion-$1.280 billion vs $1.196 billion estimate.
Benzinga Newsdesk
PRO
PTC Therapeutics Q2 EPS $0.92 Beats $0.23 Estimate, Sales $360.519M Beat $298.963M Estimate
Benzinga Newsdesk
PRO
PTC Therapeutics Raises FY2026 Sales Guidance from $700.000M-$800.000M to $1.080B-$1.180B vs $1.013B Est
PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $700.000 million-$800.000 million to $1.080 billion-$1.180 billion vs $1.013 billion estimate.
Benzinga Newsdesk
PRO
PTC Therapeutics Q1 EPS $(0.03) Beats $(0.48) Estimate, Sales $272.551M Beat $218.805M Estimate
PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.48) by 93.75 percent. This is a 100.3 percent decrease over earnings of $10.04 per share from
Benzinga Newsdesk
PRO
PTC Therapeutics Sees FY2026 Sales $700.000M-$800.000M vs $959.579M Est
PTC Therapeutics (NASDAQ:PTCT) sees FY2026 sales of $700.000 million-$800.000 million vs $959.579 million analyst estimate.
Benzinga Newsdesk
PRO
PTC Therapeutics Q4 EPS $(1.67) Misses $0.07 Estimate, Sales $164.677M Miss $276.665M Estimate
PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $0.07 by 2419.44 percent. This is a 96.47 percent decrease over losses of $(0.85) per share
Benzinga Newsdesk
